Supplementary Figures
Figure S1 | Gating strategy used for flow cytometry analysis. (A) Spleen cells were stained with mAbs against CD3, TCRb, TCRgd, and other markers, and 7-AAD, which was used to exclude dead cells. Gating strategies for ab T cells, gd T cells, CD4 + T cells, and CD8 + T cells used to analyze their relative proportions (Fig. 2) , their expression of cell-surface molecules (Fig. 3, 5) , and their metabolic status (Fig. 7) . (B) Gating strategy used with gdT cells to analyze BrdU incorporation (Fig.  4) , apoptosis (Fig. 4) , and intracellular staining (Fig. 6, 8 ). The level of serum antibodies in each mouse was determined by ELISA. Plates coated with P. yoelii extract were added with serum at a 1: 20 dilution, and specific antibodies were detected with biotin-conjugated anti-mouse IgG1, IgG2b, IgG3, or IgM antibodies. Statistical analysis was performed using unpaired t-test with Welch's correction. *p < 0.05 Figure S4 | The effect of metformin on the phenotype of αβT cells in P. yoelii-infected mice. Uninfected B6 mice or B6 mice infected with P. yoelii 17XNL, which received (Met + ) or did not receive (Met − ) metformin for 18 days, as described in Fig. 1 (3 mice/group). Splenocytes from uninfected and metformin-treated (Met + ) and untreated (Met − ) infected mice were stained for CD3, gdTCR, and other cell-surface markers. Representative plots of these molecules on ab T (CD3 + γδTCR -) cells (A) and the proportions of these populations in ab T cells are shown (B). Statistical significance was assessed using the unpaired t-test with Welch's correction. *p < 0.05; ns, not significant.
Figure S5 | Cytokine production by ab T cells in P. yoelii-infected mice. B6 mice received (red) or did not receive (blue) metformin in drinking water for 18 days (3 mice/group). (A)
Splenocytes from the infected mice were stimulated with PMA and ionomycin for 4 h; surfaced stained for CD3, CD4, and CD8; and intracellularly stained for IFN-γ, TNFα, or Granzyme B. (B) Serum was collected 18 days after infection, and the levels of IFN-g were determined by ELISA. Statistical analysis was performed using the unpaired t test. No significant difference was observed between the metformin-treated and untreated mice. 
ELISA
The levels of anti-P. yoelii IgG1, IgG2b, IgG3, and IgM antibodies were determined by ELISA. Briefly, ELISA plates were coated with freeze-thaw lysate of P. yoelii-infected red blood cells (8 × 10 6 infected RBC/ well) in PBS overnight at 4℃, and blocked with PBS containing 10% FCS for 30 minutes at room temperature. After washing plates, serum was added at 1:20 dilution and incubated 2 hrs at room temperature. Plates were washed, incubated with biotin-conjugated rabbit anti-mouse IgG1, IgG2b, or IgM antibodies (ZyMED, San Francisco, CA, USA) or biotin-conjugated rat anti-mouse IgG3 mAb (Pharmingen) at 1:1000 dilution, washed, and incubated with alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA, USA) at 1:1000 dilution. After washing, 4-Nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich, MO, USA) solution was added to each well. The optical density at 405 nm was determined using a Microplate Reader (Bio-Lad, Hercules, CA, USA).
The level of IFN-γ in serum were determine by a sandwich ELISA according to the manufacturer's directions using anti-mouse IFN-γ mAb (R4-6A2) (e-Bioscience) for capture and biotinylated antimouse IFN-γ mAb (XMG1.2) for the detection. The optical density values were determined at 405 nm using a Microplate Reader. The concentrations of IFN-γ were calculated using a standard curve made by a serial dilution of the known concentrations of recombinant mouse IFN-γ (PeproTech, NJ, USA).
